A wave of insider selling hit AMAT this week. CEO Gary Dickerson and at least five other executives filed 22 separate sell transactions on June 17. Combined, they offloaded over $80 million in shares at prices around $590–$597.
Dickerson alone accounted for more than $45 million of that total. Chairman Thomas Iannotti added another $5.5 million. CTO Omkaram Nalamasu sold nearly $10 million. The cluster of C-suite filings on a single day stands out as one of the largest coordinated insider exits seen in US equities this week.
Across town in biotech, the picture looks very different. SMMT Chairman and CEO Robert Duggan filed a $50 million purchase on June 12 — buying 3.81 million shares at $13.12. Days earlier, President Maky Zanganeh spent $1.5 million buying stock at $14.60, and CFO Manmeet Soni added two separate purchases totalling $722,000. Three C-level executives buying at the same time is a rare signal of internal confidence.
DVA CEO Javier Rodriguez also filed sales this week — two transactions worth a combined $14.5 million on June 15–16, priced near $209.
The contrast is sharp. Applied Materials insiders are cashing out near multi-year highs. Summit Therapeutics leadership is buying aggressively after a recent pullback. Markets will be watching both closely.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
